Michael C Bishop

7625909, Dec 1, 2009

May 21, 2004

10/850967

Rustum S. Boyce - San Francisco CA, US
Natalia Aurrecoechea - Oakland CA, US
Daniel Chu - Santa Clara CA, US
Aaron Smith - Union City CA, US
Christopher R. Conlee - Morrisville NC, US
Brian D. Thompson - Chapel Hill NC, US
Judith de Armas Kuntz - Raleigh NC, US
David L. Musso - Raleigh NC, US
Kevin K. Barvian - Morrisville NC, US
Stephen A. Thomson - Durham NC, US
William R. Swain - Durham NC, US
Kien S. Du - Durham NC, US
Brian A. Chauder - Raleigh NC, US
Jason D. Speake - Cary NC, US
Michael J. Bishop - Chapel Hill NC, US

Novartis Vaccines and Diagnostics, Inc. - Emeryville CA

A61K 31/517
A61K 31/519
A61P 5/50
C07D 239/88
C07D 239/95
C07D 471/04
C07D 487/04

5142662, 51426631, 544284, 544286, 544287

A variety of small molecule, guanidine-containing molecules capable of acting as MC4-R agonists are provided. The compounds are useful in treating MC4-R mediated diseases when administered to subjects. The compounds have the structure IA, IB, and IC where the values of the variables are defined herein.

20020065769, May 30, 2002

Nov 1, 2001

10/002555

Roberto Irribarren - Fremont CA, US
Michael Bishop - Mill Valley CA, US

G06F017/60

705/037000

According to one embodiment, the meeting of buyer demand that was unmet in prior bidding cycles in an on-line bidding transaction is provided. In one such embodiment, a method includes determining that a price for a quantity of business offered by at least one vendor and a price by at least one buyer for the quantity of business do not match during at least one prior bidding cycle in an on-line bidding transaction. The method also includes determining a difference between the price by the at least one vendor and the price by the at least one buyer. Additionally, the method includes generating a new bidding cycle in the on-line bidding transaction upon determining that the difference is within a range.

20100105654, Apr 29, 2010

Oct 23, 2009

12/605174

Rustum S. BOYCE - San Francisco CA, US
Natalia Aurrecoechea - Oakland CA, US
Daniel Chu - Santa Clara CA, US
Aaron Smith - Union City CA, US
Christopher R. Conlee - Morrisville NC, US
Brian D. Thompson - Chapel Hill NC, US
Judith de Armas Kuntz - Raleigh NC, US
David L. Musso - Raleigh NC, US
Kevin K. Barvian - Morrisville NC, US
Stephen A. Thomson - Durham NC, US
William R. Swain - Durham NC, US
Kien S. Du - Durham NC, US
Brian A. Chauder - Raleigh NC, US
Jason D. Speake - Cary NC, US
Michael J. Bishop - Chapel Hill NC, US

A61K 31/517
C07D 403/12
C07D 239/86
C07D 403/14
C07D 413/14
C07D 417/14
A61K 31/5377
A61P 3/04
A61P 3/10

51421021, 544287, 544284, 540575, 544119, 51425217, 5142663, 51425211, 5142345

A variety of small molecule, guanidine-containing molecules capable of acting as MC4-R agonists are provided. The compounds are useful in treating MC4-R mediated diseases when administered to subjects. The compounds have the structures VA, VB, VIIA and VIIB where the values of the variables are defined herein.

20120115909, May 10, 2012

Jul 16, 2010

13/383869

Xue Ge - Palo Alto CA, US
Hansen Wong - Sunnyvale CA, US
Wendy Huang Chern - Palo Alto CA, US
Hans Hofland - Palo Alto CA, US
Michael J. Bishop - Research Triangle Park NC, US
Xin Frank Cai - Palo Alto CA, US
Alan Colborn - Research Triangle Park NC, US

A61K 31/4436
A61P 17/10
A61P 17/06
A61K 31/4545
A61P 17/12
A61P 17/00
C07D 409/14
A61K 31/444
C07D 409/10
A61P 17/08

514318, 5462801, 514337, 546256, 514332, 546194

The presently described subject matter relates to new derivatives of tazarotene that also exhibit retinoid activity, pharmaceutical compositions comprising the derivatives, method of treating skin disorders with the pharmaceutical compositions, and process of making the derivatives.

20220288069, Sep 15, 2022

Jul 17, 2020

17/626486

- San Jose CA, US
Ping Cao - San Jose CA, US
Michael J. Bishop - San Jose CA, US

A61K 31/506
C07D 403/12
C07D 413/14
C07D 403/14
C07D 417/12
C07D 417/14
C07D 403/06
C07D 209/34
A61K 45/06
A61K 31/5377
A61K 31/4439
A61K 31/404

The present disclosure provides compounds and compositions thereof which are useful as inhibitors of tyrosine kinase and which exhibit desirable characteristics for the same. Further disclosed herein are methods of treating cancer using these tyrosine kinase inhibitor compounds.

20220218703, Jul 14, 2022

Feb 14, 2020

17/430621

- Sunnyvale CA, US
Chao Zhang - Sunnyvale CA, US
Michael J. Bishop - Sunnyvale CA, US

A61K 31/506
A61K 45/06
C07D 405/14
C07D 401/04
C07D 401/14

The disclosure provides novel FGFR inhibitors based on the pyridinylpyrimidine. The disclosure includes inhibitors with broad inhibitory activity against all FGFR isoforms, and inhibitors with selective inhibition against FGFR4. These novel pyridinylpyrimidine-based FGFR inhibitors, or their derivatives, have strong potential to be used to treat cancer.

20210018432, Jan 21, 2021

Oct 5, 2020

17/063483

- Cupertino CA, US
Mark Alan Arbore - Los Altos CA, US
David I. Simon - San Francisico CA, US
Michael J. Bishop - San Carlos CA, US
James W. Hillendahl - Vacaville CA, US
Robert Chen - Mountain View CA, US

G01N 21/27
G01N 21/35
G01N 21/47
G01J 3/32
G01J 3/36
G01J 3/433
G01J 3/447
G01J 3/02
G01J 3/42

This relates to systems and methods for measuring a concentration and type of substance in a sample at a sampling interface. The systems can include a light source, optics, one or more modulators, a reference, a detector, and a controller. The systems and methods disclosed can be capable of accounting for drift originating from the light source, one or more optics, and the detector by sharing one or more components between different measurement light paths. Additionally, the systems can be capable of differentiating between different types of drift and eliminating erroneous measurements due to stray light with the placement of one or more modulators between the light source and the sample or reference. Furthermore, the systems can be capable of detecting the substance along various locations and depths within the sample by mapping a detector pixel and a microoptics to the location and depth in the sample.

20190250041, Aug 15, 2019

Apr 26, 2019

16/396217

- Cupertino CA, US
Michael J. BISHOP - San Carlos CA, US
Robert CHEN - Mountain View CA, US
David I. SIMON - San Francisco CA, US
George Dee SKIDMORE - Richardson TX, US

G01J 5/08
G01J 4/04
G01J 5/02
G01J 5/20

This relates to sensor systems, detectors, imagers, and readout integrated circuits (ROICs) configured to selectively detect one or more frequencies or polarizations of light, capable of operating with a wide dynamic range, or any combination thereof. In some examples, the detector can include one or more light absorbers; the patterns and/or properties of a light absorber can be configured based on the desired measurement wavelength range and/or polarization direction. In some examples, the detector can comprise a plurality of at least partially overlapping light absorbers for enhanced dynamic range detection. In some examples, the detector can be capable of electrostatic tuning for one or more flux levels by varying the response time or sensitivity to account for various flux levels. In some examples, the ROIC can be capable of dynamically adjusting at least one of the frame rate integrating capacitance, and power of the illumination source.